
Transcranial LED light therapy, sometimes called photobiomodulation, is one of the safe alternative therapies the BART Foundation believes may help brain injury survivors. Like Hyperbaric Oxygen Therapy (HBOT), there are already some FDA-approved applications, but these do not include TBI/ABI. The BART Foundation aims to promote better outcomes for TBI/ABI survivors by answering three questions: which alternative therapies are likely to work, where they can be found, and how they can be afforded. One of the ways we fulfill our mission is by carefully watching global research and clinical trial outcomes and sharing that information, in user-friendly language, with the TBI/ABI community.
Because of our mission, we want to share with you a recent research article published in June 2026 in the journal Lasers in Dental Science, where researchers from Universidade de São Paulo, São Paulo, Brazil, and the University of Johannesburg, Johannesburg, South Africa, analyzed the scientific literature published between 2000 and 2024 on transcranial photobiomodulation therapy (tPBMT). Seven studies published during this period met the eligibility criteria for in-depth qualitative analysis, including clinical, experimental, and review-based investigations involving traumatic brain injury, neurodegenerative disorders, and psychiatric conditions.
The synthesized findings from these seven studies demonstrated positive cognitive, motor, vascular, and neurophysiological effects associated with transcranial photobiomodulation therapy (tPBMT). Near-infrared wavelengths, particularly approximately 810 nm, were most commonly employed, but the seven studies had variability in thewavelengths used. While a lack of standardized treatment protocols limit its clinical translation, tPBMT continues to gather promising evidence as a non-invasive therapeutic approach for neurological and neuropsychiatric disorders.
If you’d like to learn more about this promising treatment, visit our YouTube channel to watch our 2025 webinar with Dr. Marvin Berman titled “Healing with Light: The principle drivers behind photobiomodulation’s therapeutic effectiveness.” We also encourage you to watch this marvelous YouTube video by Michael Hamblin, Ph.D. Dr. Hamblin was a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital, an Associate Professor of Dermatology at Harvard Medical School, and is now a Distinguished Visiting Professor at the University of Johannesburg, South Africa. In this 25-minute video, he explains the history of photobiomodulation, the mechanisms involved, and the clinical support for it as therapy for many kinds of TBI/ABI.